| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| HAWK / HARRIER |
1,817 (1,082 HAWK 743 HARRIER) |
Alcon Research | 2018 |
Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72-84. https://www.aaojournal.org/article/S0161-6420(18)33018-5/fulltext |
|